BioSpace News Archive

University of Waterloo researchers suggest combining ibuprofen with a diuretic and an RSA inhibitor for high blood pressure could place people at risk for kidney disease.

Modular Devices Acquisition, LLC (Modular Devices), a leading provider of mobile cath labs and mobile cleanrooms, today announced the acquisition of Cardiac Services Mobile, Inc. (Cardiac Services Mobile), a mobile cath lab company out of Nashville, TN that serves the US markets.

Affimed N.V. announced that the American Society of Clinical Oncology has informed the Company’s collaborator that it has removed the previously announced oral presentation on AFM13-104, the investigator sponsored trial that evaluates AFM13 pre-complexed with NK cells in patients with relapsed/refractory CD30-positive lymphomas, from the upcoming conference program.

Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced its participation in the upcoming investor conferences.

Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will present at two upcoming investor conferences in May.

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to four new employees with a grant date of May 2, 2022, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Cytovia Therapeutics, LLC (“Cytovia Therapeutics”), a global biotechnology company focused on harnessing the power of natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that it will be presenting at the AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer.

Neuronetics, Inc. announced the granting of inducement awards to eight new non-executive employees.

Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a conference call on Monday, May 9, 2022 at 10:30 a.m. ET to review top-line clinical data from its “ASTRAEUS” Phase 2 Study of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema.

Gritstone bio, Inc. reported financial results for the first quarter ended March 31, 2022 and reviewed business highlights.